What is the recommended initial workup and management of iron deficiency in a non‑dialysis patient with chronic kidney disease (stages 3–5)?

Iron Deficiency in Non-Dialysis CKD (Stages 3–5): Workup and Management

In non-dialysis CKD patients with anemia (hemoglobin < 11 g/dL), iron should be administered to maintain ferritin ≥ 100 ng/mL and transferrin saturation ≥ 20%, with either oral or intravenous iron being appropriate depending on tolerance and response. 1

---

Initial Diagnostic Workup

Laboratory Assessment

• Measure serum ferritin and transferrin saturation (TSAT) as the primary iron indices; these are more reliable than serum iron or TIBC in CKD patients. 2, 3
• Absolute iron deficiency in non-dialysis CKD is defined as TSAT ≤ 20% and ferritin ≤ 100 ng/mL. 1, 2, 4
• Functional iron deficiency (iron-restricted erythropoiesis) is characterized by TSAT ≤ 20% with ferritin 100–300 ng/mL, indicating adequate stores but insufficient mobilization due to elevated hepcidin. 4, 5
• Obtain a complete blood count with hemoglobin, hematocrit, and MCV to assess severity of anemia. 2
• Check C-reactive protein to identify inflammation, which can falsely elevate ferritin and mask true iron deficiency. 3

Diagnostic Thresholds Specific to CKD

• The diagnostic criteria for iron deficiency differ in CKD compared to the general population; ferritin thresholds are higher because chronic inflammation elevates ferritin independently of iron stores. 1, 4
• In CKD stages 3–5 not on dialysis, ferritin < 100 ng/mL with TSAT ≤ 20% confirms absolute iron deficiency requiring treatment. 2, 4
• Ferritin 100–300 ng/mL with TSAT < 20% suggests functional iron deficiency, where hepcidin blocks iron mobilization despite adequate stores. 4, 5

---

Management Algorithm

Step 1: Determine Iron Status and Hemoglobin Level

• If hemoglobin < 11 g/dL and ferritin < 100 ng/mL or TSAT < 20%, initiate iron supplementation. 1, 2
• If hemoglobin ≥ 11 g/dL, iron therapy is generally not indicated unless the patient is receiving or about to start erythropoiesis-stimulating agents (ESAs). 1

Step 2: Choose Route of Iron Administration

Oral Iron (First-Line for Non-Dialysis CKD Stages 3–5)

• Ferrous sulfate 200 mg (≈65 mg elemental iron) once daily is the preferred oral regimen due to cost-effectiveness and comparable efficacy to other formulations. 6
• Once-daily dosing is superior to multiple daily doses because hepcidin remains elevated for ~48 hours after iron intake, blocking subsequent absorption and increasing gastrointestinal side effects. 6
• Add vitamin C 500 mg with each iron dose to enhance absorption, especially when TSAT is markedly low. 6
• Alternative oral formulations (ferrous fumarate, ferrous gluconate, ferric citrate, ferric maltol) may be used if ferrous sulfate is not tolerated. 6, 7, 8
• Ferric citrate is FDA-approved for non-dialysis CKD with iron-deficiency anemia and also serves as a phosphate binder; it improves hemoglobin and iron parameters with good tolerability. 7, 8

Intravenous Iron (Preferred in Specific Scenarios)

• Switch to IV iron when:

  • Intolerance to at least two different oral iron preparations. 6
  • Ferritin fails to improve after 4 weeks of compliant oral therapy. 6
  • Hemoglobin fails to rise by ≥ 1 g/dL after 4–8 weeks of oral iron. 6
  • Active inflammatory bowel disease with hemoglobin < 10 g/dL (hepcidin-mediated absorption blockade). 6
  • Estimated GFR < 30 mL/min/1.73 m² (CKD stage 4–5), where oral absorption is often impaired. 3, 9
  • Patient is receiving or about to start ESA therapy and requires rapid iron repletion. 1, 9

• Preferred IV iron formulations:

  • Ferric carboxymaltose: 750–1000 mg per 15-minute infusion; two doses ≥7 days apart provide 1500 mg total. 10, 8
  • Ferric derisomaltose: 1000 mg as a single infusion. 10, 8
  • These formulations allow repletion in 1–2 sessions, minimizing infusion-related risk and improving convenience. 6, 10

• Avoid iron dextran as first-line due to higher anaphylaxis risk (≈0.6–0.7%). 6, 8

• All IV iron must be administered in a setting equipped with resuscitation facilities. 6

---

Monitoring and Treatment Targets

Expected Hematologic Response

• Hemoglobin should rise by ≈2 g/dL after 3–4 weeks of adequate iron therapy (oral or IV). 6, 10
• In the REPAIR-IDA trial (Trial 2), non-dialysis CKD patients receiving ferric carboxymaltose achieved a mean hemoglobin increase of 1.1 g/dL from baseline to highest value by Day 56. 10

Iron Parameter Targets

• Maintain ferritin ≥ 100 ng/mL to ensure sufficient iron stores. 1, 2
• Maintain TSAT ≥ 20% to confirm adequate iron availability for erythropoiesis. 1, 2
• After IV iron, ferritin and TSAT increase significantly; in Trial 2, mean ferritin rose by 735 ng/mL and TSAT by 30% prior to Day 56. 10

Monitoring Schedule

• Recheck hemoglobin and iron indices 4 weeks after starting therapy. 6
• If oral iron is used, continue for 3 months after hemoglobin normalizes to fully replenish stores; total treatment duration is typically 6–7 months. 6
• Monitor hemoglobin and red-cell indices every 3 months during the first year, then annually thereafter. 6
• Do not measure iron parameters within 4 weeks of IV iron infusion, as circulating iron can falsely elevate results. 3

---

Special Considerations in CKD

Functional Iron Deficiency and Hepcidin

• Elevated hepcidin in CKD (due to inflammation and reduced renal clearance) blocks intestinal iron absorption and impairs iron mobilization from reticuloendothelial stores, causing functional iron deficiency. 4, 9, 5
• This explains why oral iron is often ineffective in advanced CKD; IV iron bypasses hepcidin-mediated blockade. 9, 5

Use with Erythropoiesis-Stimulating Agents (ESAs)

• Iron supplementation is essential when ESAs are used, as ESA-driven erythropoiesis rapidly depletes iron stores. 1, 9
• In patients requiring high ESA doses (≥300 IU/kg/week epoetin α or ≥1.5 mg/kg/week darbepoetin α) with ferritin > 800 ng/mL and TSAT < 25%, consider administering iron to increase hemoglobin, but carefully weigh risks versus benefits. 1

Adverse Effects of IV Iron

• Hypophosphatemia and 6H syndrome (high FGF-23, hypophosphatemia, hyperphosphaturia, hypovitaminosis D, hypocalcemia, secondary hyperparathyroidism) can occur with ferric carboxymaltose and ferric derisomaltose; monitor phosphate levels. 8
• True anaphylaxis with IV iron is rare (0.6–0.7%); most reactions are complement-activation pseudo-allergies that respond to slowing the infusion rate. 6, 8

---

Critical Pitfalls to Avoid

• Do not prescribe multiple daily doses of oral iron; this increases side effects without improving efficacy due to hepcidin-mediated absorption blockade. 6
• Do not discontinue iron therapy when hemoglobin normalizes; continue for an additional 3 months to restore iron stores. 6
• Do not persist with oral iron beyond 4 weeks without a hemoglobin rise; reassess for malabsorption, ongoing loss, or need for IV iron. 6
• Do not overlook vitamin C supplementation when oral iron response is suboptimal. 6
• Do not rely on serum iron or TIBC alone to diagnose iron deficiency in CKD; ferritin and TSAT are more reliable. 2, 3
• Do not use the same ferritin thresholds as in the general population; CKD requires higher cutoffs (≥100 ng/mL) due to chronic inflammation. 1, 2, 4

---

Failure-to-Respond Algorithm

If anemia persists after 6 months of appropriate iron therapy:

• Verify adherence to oral iron therapy. 6
• Evaluate for ongoing blood loss (gastrointestinal, urinary tract). 6
• Consider malabsorption syndromes (celiac disease, inflammatory bowel disease). 6
• Check for concurrent vitamin B12 or folate deficiency. 6
• Assess for systemic disease, bone-marrow pathology, or hemolysis. 6
• Seek nephrology or hematology consultation for complex or refractory cases. 6